BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240310T080000
DTEND;TZID=Europe/Stockholm:20240314T170000
DTSTAMP:20260429T221108
CREATED:20231115T134814Z
LAST-MODIFIED:20240306T094116Z
UID:31573-1710057600-1710435600@senzagen.com
SUMMARY:2024 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #732\nDiscuss your testing needs with us\n  \nExhibitor-Hosted Session\nExpert round table on NAMs and industry trends\nTuesday\, 12 Mar | 9:00 am-10:00 am\n \n \nPosters\nSpotlight on PoD\, NESILs\, product development and CE-marking of Medical Devices\nMonday\, 11 Mar | 9:15 am-11:15 am\n🎫 Joint poster with Sonova\nP487 #3362 | Unveiling skin sensitizing potential: case studies on biocompatible material development utilizing the in vitro GARD®skin Medical Device assay \n🎫 Joint poster with Duearity\nP480 #3355 | Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment \n🎫 Joint poster presented by RIFM\nP318 #3205 | Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARD®skin Dose-Response assay \nTuesday\, 12 Mar | 2:15 pm-4:15 pm\n🎫 Joint poster with L’Oréal\nP739 #4190 | Improved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 Joint poster presented by IFF\nP762 #4213 | A Next Generation Risk Assessment (NGRA) Framework to conduct Quantitative Risk Assessment (QRA2) to determine safe use levels of fragrance ingredients in cosmetic products \n🎫 Joint poster presented by Inotiv\nP738 #4189 | Testing of Regulatory-Relevant Chemicals for Skin and Respiratory Sensitization Hazard \n\n 
URL:https://senzagen.com/event/sot-annual-meeting-2024-toxexpo/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/11/SOT2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240207T160000
DTEND;TZID=Europe/Stockholm:20240207T170000
DTSTAMP:20260429T221108
CREATED:20240116T102331Z
LAST-MODIFIED:20240116T145019Z
UID:31853-1707321600-1707325200@senzagen.com
SUMMARY:Webinar: Spotlight on Difficult-to-Test samples
DESCRIPTION:Join our upcoming webinar to explore the recent advancement in GARD® for Skin Sensitization assessment\, with a specific focus on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. \nOur skin sensitization experts will address challenges posed by various Difficult-to-Test substances\, discussing the applicability domain of key event-based NAMs and existing test strategies. \nYou will learn about the broad applicability of GARD®skin OECD TG442E as we present scientific data on Difficult-to-Test substances and exciting projects done in collaboration with industry partners: \nAgrochemical Formulations | Formulated Lubricant Products | Indirectly Acting Haptens | Metals | Natural Extracts | Polymers | UVCBs  \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey takeaways\n\nNAMs and test strategies for skin sensitization testing of Difficult-to-Test samples.\nThe applicability domain of GARD®skin for challenging substances and its integration into Defined Approaches.\nCase studies on Agrochemical Formulations\, Formulated Lubricant Products\, Indirectly Acting Haptens\, Metals\, Natural Extracts\, Polymers\, and UVCBs.\n\nWhat are “difficult-to-test” substances?\nIn the context of skin sensitization testing\, certain groups of chemicals are considered difficult to test using conventional cell-based methods. Examples of commonly recognised “difficult-to-test” samples include indirectly acting haptens\, complex mixtures\, and substances with low water solubility. \nRead more about difficult-to-test substances. \nSpeakers\n \n  \n \n 
URL:https://senzagen.com/event/webinar-spotlight-on-difficult-to-test-samples/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/banner-website-v5-with-dates-1-e1705416604964.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231214T160000
DTEND;TZID=Europe/Stockholm:20231214T170000
DTSTAMP:20260429T221108
CREATED:20231114T150216Z
LAST-MODIFIED:20231121T211556Z
UID:31504-1702569600-1702573200@senzagen.com
SUMMARY:Webinar: Safety of acrylate monomers\, metals\, and other materials used in medical device development
DESCRIPTION:Join our upcoming free webinar to explore the effective utilization of in vitro methods for safety assessment of materials during product development of Medical Devices.\nWe will discuss recent advancements in in vitro methods for assessing the endpoints of skin irritation and skin sensitization. Learn how to integrate these assessments into your product development process as a complement to chemical characterization and cytotoxicity testing. \nDiscover how this approach can aid in: \nSelecting the right material | Developing new materials | Optimizing production | Choosing the appropriate sterilization method\n\nKey takeaways\n\n*Gain insights into the key fundamentals of the biological evaluation of medical devices and the availability of in vitro biocompatibility testing. \n*Explore the applicability of the in vitro GARD technology in the assessment of medical devices\, supporting both polar and non-polar extraction vehicles (ISO 10993-12). \n*Examine user cases illustrating the safety assessment of acrylate monomers\, metals\, and various materials utilized in medical device development. Learn how these assessments contribute to material selection and production optimization. \n\nSpeakers\n\n \n 
URL:https://senzagen.com/event/webinar-safety-of-acrylate-monomers-metals-and-other-materials-used-in-medical-device-development/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/11/Webinar-banner-v10-without-date_MD-product-development.png.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231116
DTEND;VALUE=DATE:20231118
DTSTAMP:20260429T221108
CREATED:20230824T072405Z
LAST-MODIFIED:20231108T143625Z
UID:30942-1700092800-1700265599@senzagen.com
SUMMARY:Annual Medical Device Biocompatibility Conference
DESCRIPTION:Presentation \n\nThe GARD®skin Medical Device assay for assessing the skin sensitizing potential of medical devices: A case study on the use of in vitro data in the biological evaluation for CE marking according to MDR\n\nKey Points \n\nA proof-of-concept study using the GARD®skin Medical Device assay to evaluate the skin sensitizing potential of medical device materials according to ISO 10993-10.\nA case study using in vitro data for the endpoints of cytotoxicity\, skin irritation and skin sensitization in the biological evaluation for CE-marking according to MDR to avoid animal testing while accelerating time to market.
URL:https://senzagen.com/event/annual-medical-device-biocompatibility-conference/
LOCATION:Berlin\, Germany
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/bicompatibility_berlin.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20260429T221108
CREATED:20230824T070701Z
LAST-MODIFIED:20231109T141151Z
UID:30935-1699747200-1700092799@senzagen.com
SUMMARY:ACT 2023 Annual Meeting
DESCRIPTION:→ Booth #333\nSpotlight on difficult-to-test samples and in vitro quantitative potency assessment as an alternative to the Local Lymph Node Assay\nCome meet us at booth #333 and join our poster presentation to learn how the GARD assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment\, providing a high performing and ethical alternative to animal testing. \n→ Joint poster with Takasago\nQuantitative potency assessment of skin sensitizers when developing novel fragrance ingredients\nPractical application of the GARDskin Dose-Response assay to derive a No Expected Sensitization Induction Level (NESIL) value for confirmatory human patch studies to determine safe use level for novel fragrance ingredients \n→ Hot topic\nIn vitro tests supporting Occupational Health\nOccupational allergic dermatitis and asthma are common workplace diseases. By using the in vitro GARD® assays to test for skin and respiratory sensitizers in combination\, it is possible to identify allergens in the work environment and take preventive action. \nCome by our booth to learn more! \n→ Discuss your toxicological risk assessment needs with us!\nMeet our in vitro experts\, Dr Andy Forreryd and Dr Tim Lindberg
URL:https://senzagen.com/event/act-2023-annual-meeting/
LOCATION:Orlando\, Florida\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/banner_ACT2023-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231018T160000
DTEND;TZID=Europe/Stockholm:20231018T170000
DTSTAMP:20260429T221108
CREATED:20231002T134126Z
LAST-MODIFIED:20231002T155151Z
UID:31216-1697644800-1697648400@senzagen.com
SUMMARY:Webinar: Latest GARD® innovation and research in in vitro skin and respiratory sensitization
DESCRIPTION:We invite you to participate in our webinar where new cutting edge GARD results will be explained by the experts at SenzaGen and our partners.\nIn case you missed SenzaGen’s Scientific Posters and Oral Presentations at this year’s WC12 in Niagara Falls or Eurotox in Ljubljana\, we are pleased to offer you a new opportunity to participate on Oct 18\, 2023! \nCome and join us to explore the most recent GARD® data on skin sensitization\, presented by Emily N Reinke from Inotiv-RTP\, a project done in collaboration with NIH and Burleson Research Technologies. \nAdditionally\, we will showcase our most recent collaborative projects with industry partners: \nMerck| Johnson Matthey | Corteva Agriscience | ExxonMobil Biomedical Sciences | International Flavors & Fragrances (IFF) | Duearity | Inotiv-RTP \n  \n \n  \nKey topics \n\nDifficult-to-Test Samples\nUVCBs and Formulated Lubricant Products\nAgrochemical Formulations\nComplex Mixtures\nMetals\nQuantitative Potency Assessments\nRegulatory Acceptance According to MDR\nProtein Allergens\n\n  \nSpeakers \n \n  \nRegister here \n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.\n\n 
URL:https://senzagen.com/event/webinar-latest-gard-innovation-and-research-in-in-vitro-skin-and-respiratory-sensitization/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/10/Lime_webinarium_WC12-and-2023-Eurotox-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230913
DTEND;VALUE=DATE:20230914
DTSTAMP:20260429T221108
CREATED:20230823T145738Z
LAST-MODIFIED:20230823T145738Z
UID:30926-1694563200-1694649599@senzagen.com
SUMMARY:The Fragrance Science & Advocacy Council (FSAC) In-person Workshop
DESCRIPTION:Dermal Sensitizers: A Workshop on State of the Science and Utilization of New Approach Methodologies for Quantitative Risk Assessment\n 
URL:https://senzagen.com/event/the-fragrance-science-advocacy-council-fsac-in-person-workshop/
LOCATION:Arlington\, Virginia\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/08/FSAC-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230910T080000
DTEND;TZID=Europe/Stockholm:20230923T170000
DTSTAMP:20260429T221108
CREATED:20230313T144734Z
LAST-MODIFIED:20230831T110511Z
UID:30473-1694332800-1695488400@senzagen.com
SUMMARY:Eurotox 2023
DESCRIPTION:New opportunities for skin sensitization testing with GARD®skin OECD TG 442E\nCome meet us at booth #36 and join our poster presentations to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development.\nMeet also ToxHub\, our latest addition to the Group\, and benefit from expert Toxicology and Regulatory advice.\nBooth #36\n\nDiscuss your toxicological risk assessment needs with us!\n\n \n \nPosters\n\nSpotlight on Difficult-to-Test\, Quantitative Potency\, Medical Devices and E&L Assessment\n\n→ Joint poster with Exxon Mobil\nP07-02 | Assessing the utility of the Genomic Allergen Rapid Detection (GARD®skin) assay to detect dermal sensitization potential in UVCBs and formulated lubricant products \n→ Joint poster with IFF and RIFM\nP22-43 | The GARD® skin Dose-Response assay for determination of a point-of-departure (PoD) for Next Generation Risk Assessment (NGRA) of skin sensitizers: A case study using isocyclocitral \n→ Joint poster with Duearity\nP22-30 | Regulatory approval of medical devices according to MDR using in vitro data from GARD® skin Medical Device for skin sensitization assessment \n→ ToxHub poster\nLP-38 | Toxicological risk assessment of extractable and leachable compounds: mitigating risks in pharmaceutical applications \nNew\n\nTailored Toxicology Services\n\nAt our booth\, you will also meet our independent consultancy unit Toxhub\, specialized in toxicological risk assessment and regulatory strategy consulting\, with expertise in pharmaceuticals\, chemicals\, medical devices and cosmetics. \nExplore ToxHub’s services \n 
URL:https://senzagen.com/event/eurotox-congress-2023/
LOCATION:Ljubljana\, Slovenia\, Slovenia
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/03/Eurotox23v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230910
DTEND;VALUE=DATE:20230914
DTSTAMP:20260429T221108
CREATED:20230823T144809Z
LAST-MODIFIED:20230824T070750Z
UID:30921-1694304000-1694649599@senzagen.com
SUMMARY:Occupational Toxicology Roundtable 2023
DESCRIPTION:
URL:https://senzagen.com/event/occupational-toxicology-roundtable-2023/
LOCATION:Cleveland\, Ohio\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/08/OTR2023.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230831T080000
DTEND;TZID=Europe/Stockholm:20230904T170000
DTSTAMP:20260429T221108
CREATED:20230313T144259Z
LAST-MODIFIED:20230831T105454Z
UID:30467-1693468800-1693846800@senzagen.com
SUMMARY:WC12
DESCRIPTION:12th World Congress on Alternatives and Animal Use in the Life Sciences\nOur team and partners will feature the GARD® assays in several posters and presentations. Join us to explore new scientific data and exciting projects done in collaboration with industry partners.\nSymposia\n\nSpotlight on Medical Devices\, Complex Samples and Dose-Response\n\nWednesday\, Aug 30\, 11:00 – 12:30\, Session S410\n→ In collaboration with Duearity\n#515 Application of the GARD®skin Medical Device assay for regulatory approval of medical devices according to MDR \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ In collaboration with RIFM and IFF\n#208 In vitro determination of a point of departure for Next Generation Risk Assessment (NGRA) of skin sensitizers: Reproducibility and precision of the GARD®skin Dose-Response assay \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ Presented by Emily N Reinke\, Inotiv-RTP\, in collaboration with NIH and Burleson Research Technologies\n#90 Evaluating Skin Sensitization Hazard of Diverse Chemicals Using GARD®skin \nPosters\n\nSpotlight on Complex Mixtures\, Metals and Protein Allergens\n\nTuesday\, Aug 29\, 12:30 – 14:00\n→ Joint poster with Corteva Agriscience\nA33 #230 | GARD®: a study to investigate the applicability domain for agrochemical formulations \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Johnson Matthey\nF81 #55 | Expanding the applicability domain of NAMs for skin sensitization testing: a case study using GARD®skin for assessment of metals \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Merck\nF80 #498 | Characterization of respiratory sensitizing properties of the protein Subtilisin\, using GARD®air \nMeet our team\n\nMeet and greet with Andy Forreryd
URL:https://senzagen.com/event/12th-world-congress-on-alternatives-and-animal-use-in-the-life-sciences-wc12/
LOCATION:Niagara Falls\, Canada\, Niagara Falls\, Canada
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Number-logo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230622
DTSTAMP:20260429T221108
CREATED:20230607T072453Z
LAST-MODIFIED:20230607T072928Z
UID:30813-1687219200-1687391999@senzagen.com
SUMMARY:MedTech Summit 2023
DESCRIPTION:Biocompatibility for Medical Devices\nTuesday\, 20 June 2023 12:00 – 12:30 \n\nThe GARDskin Medical Device assay for assessing the skin sensitizing potential of medical devices: A case study on the use of in vitro data in the biological evaluation for CE marking according to MDR\n\n\nA proof-of-concept study using the GARDskin Medical Device assay to evaluate the skin sensitizing potential of medical device materials using both polar and non-polar extraction vehicles (ISO 10993-12).\nA case study using in vitro data for the endpoints of cytotoxicity\, skin irritation and skin sensitization in the biological evaluation for CE-marking according to MDR to avoid animal testing while accelerating time to market\n\nSpeaker \n\n\nDr Andy Forreryd\nScientific Liason at SenzaGen
URL:https://senzagen.com/event/medtech-summit-2023/
LOCATION:Brussels\, Belgium
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/06/MedTechSummit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230615
DTEND;VALUE=DATE:20230616
DTSTAMP:20260429T221108
CREATED:20230602T121642Z
LAST-MODIFIED:20230607T084110Z
UID:30803-1686787200-1686873599@senzagen.com
SUMMARY:Skin Sensitization by Altertox Academy
DESCRIPTION:This two days hands-on training is hosted by acCELLerate. \nSkin sensitization is a complex systemic process and since several years\, methods to replace animal tests have been validated and adopted by the OECD in this regard. These tests can be used as part of a weight-of-evidence or integrated using a Defined Approach (DA) to assess Skin Sensitization. \nAgenda\n09:55-10:25 GARD\, SenzaGen\n13:30-14:30 GARD – Case studies\, SenzaGen \nRegistration fee includes the participant booklet\, catering and social dinner. \nRegister here \n 
URL:https://senzagen.com/event/skin-sensitization-by-altertox-academy/
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/06/square-accellerate-2023.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230612T160000
DTEND;TZID=Europe/Stockholm:20230612T170000
DTSTAMP:20260429T221108
CREATED:20230524T114652Z
LAST-MODIFIED:20230524T114819Z
UID:30777-1686585600-1686589200@senzagen.com
SUMMARY:Webinar: Time for a Change: Evidence-Based Approaches for the Biological Safety Assessment of Medical Devices
DESCRIPTION:Join this free webinar where Ron Brown\, toxicologist and former FDA risk assessor\, will outline the need for a new and more agile approach for the biological safety assessment of medical devices.\nThis presentation will identify the limitations associated with the current approach\, which largely relies on animal-based tests that may have questionable clinical relevance. It will also describe how new and existing biocompatibility test methods can be evaluated following the principles of an evidence-based toxicology (EBT).\nYou will also learn how to incorporate New Approach Methodologies (NAMs) into a streamlined workflow for the safety assessment of medical devices\, which may decrease the time needed for regulatory approval of a device.\n \nKey takeaways \n\nThe limitations associated with animal-based approaches used to assess the biological safety of medical devices.\nHow to assess the validity of NAMs by using an evidence-based toxicology (EBT) approach.\nHow to incorporate NAMs into a streamlined workflow for medical device safety assessment.\nA case study on the OECD approval of the in vitro assay GARDskin and its applicability for Medical Device assessments supporting both polar and non-polar extraction vehicles (ISO 10993-12).\n\nSpeakers \n \n\nRegister here \n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.
URL:https://senzagen.com/event/webinar-time-for-a-change-evidence-based-approaches-for-the-biological-safety-assessment-of-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/Lime_webinarium_12-JUNE.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230524T160000
DTEND;TZID=Europe/Stockholm:20230524T170000
DTSTAMP:20260429T221108
CREATED:20230510T075904Z
LAST-MODIFIED:20230511T080404Z
UID:30647-1684944000-1684947600@senzagen.com
SUMMARY:Webinar: Using in vitro data in your CE marking submission of Medical Devices
DESCRIPTION:Join this free webinar to learn how you can avoid animal testing and accelerate time to market by using results from in vitro testing for the endpoints of cytotoxicity\, skin irritation and skin sensitization in your biological evaluation for CE-marking of your medical device in line with the EU Medical Device Regulation 2017/745\, the MDR.\n\nKey takeaways \n\nAn introduction to how in vitro testing can be used in the biological evaluation of your medical device with focus on cytotoxicity\, skin irritation and skin sensitization according to MDR.\nThe unique and broad applicability of the OECD approved GARD® assay for skin sensitization testing\, supporting polar and non-polar extraction vehicles as recommended in ISO 10993-12.\nSeveral application examples and a class IIa product CE marking case study supporting ethical test solutions and faster time to market.\nExpert advisory and support in compilation of regulatory documentation for instance gap analysis of ISO standards\, Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER).\n\nSpeakers \n \n\nRegister here\n\n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.
URL:https://senzagen.com/event/webinar-using-in-vitro-data-in-your-ce-marking-submission-of-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/9maj_Lime-_ToxHub_banner_line-e1683643826658.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230513
DTEND;VALUE=DATE:20230514
DTSTAMP:20260429T221108
CREATED:20230511T074528Z
LAST-MODIFIED:20230511T075952Z
UID:30750-1683936000-1684022399@senzagen.com
SUMMARY:ISID 2023 Tokyo Satellite Meeting on Dermal Sensitization & Photoallergenicity
DESCRIPTION:This three-hour event kicks off with a welcome from Expert Panel for Fragrance Safety members Yoshiki Tokura\, MD\, PhD\, Donald V. Belsito\, MD\, and Magnus Bruce\, MD\, PhD\, and an introduction from RIFM’s President\, Anne Marie Api\, PhD\, ATS.\nSession \nDermal Sensitization & Photoallergenicity\n4:05-7:05 pm\, Saturday\, May 13\, 2023\nEminence Hall\, South Tower\, 5th Floor\, Keio Plaza Hotel\, Tokyo \n  \nSpeakers \nPresentations from international experts in toxicology and dermatology will include: \n\nMechanisms of Contact Dermatitis\, Kenji Kabashima\, MD\, PhD\, Kyoto Univ.\nRIFM Dermal Sensitization Program\, Isabelle Lee\, PhD\, RIFM\nOverview RIFM Photoallergy Research Program\, Gretchen Ritacco\, MS\, RIFM\nTrial for development of photo safety assessment system in Shiseido\, Shiho Oeda\, Shiseido\nRIFM-IIVS Photoallergy Research\, Allison Hilberer\, MS\, DABT\, IIVS\nRIFM-SenzaGen Photoallergy Research\, Andy Forreryd\, PhD\, SenzaGen
URL:https://senzagen.com/event/isid-2023-tokyo-satellite-meeting-on-dermal-sensitization-photoallergenicity/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/05/ISID.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230426T160000
DTEND;TZID=Europe/Stockholm:20230426T170000
DTSTAMP:20260429T221108
CREATED:20230328T144209Z
LAST-MODIFIED:20230330T133759Z
UID:30497-1682524800-1682528400@senzagen.com
SUMMARY:SOT2023 Recap Webinar
DESCRIPTION:In case you missed SenzaGen’s Scientific Session at this year’s SOT\, here is a new opportunity! \nTogether with guest speakers from ExxonMobil Biomedical Sciences Inc. and Research Institute for Fragrance Materials\, Inc. (RIFM)\, SenzaGen’s Andy Forreryd\, PhD will present the latest GARD® data on quantitative risk assessment and regulatory testing of skin sensitizers\, and the potential to further broaden the GARD® applicability. \n\nKey topics\n\n·        Quantitative potency assessments\n·        UVCBs and formulated lubricant products\n·        Agrochemical formulations\n·        Acrylate monomers\n·        Regulatory acceptance according to MDR\n·        New application: Photosensitization \n  \n\nSpeakers\n\nAssessing the Utility of the GARD®skin Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products  \nAllison Greminger\, PhD\, DABT\nToxicology Associate @ExxonMobil Biomedical Sciences Inc.\nDr. Greminger is a board-certified toxicologist who provides scientific and regulatory support to several ExxonMobil Product Solutions businesses. In her current position\, she reviews and evaluates toxicological data to support regulatory compliance for current products\, as well as guide new product development. Dr. Greminger has a specific interest in local hazards relevant for formulated products and has conducted various research on implementing non-animal testing strategies to inform hazard potential. \n  \nAn introduction to photosensitization and why there is a need for development of predictive assays capable of discriminating between photosensitization and photoirritancy \n\nGretchen Ritacco\nPrincipal toxicologist @Research Institute for Fragrance Materials\, Inc. (RIFM)\nGretchen Ritacco leads the Photosafety program at the Research Institute for Fragrance Materials (RIFM). Her duties include evaluating fragrance materials in support of RIFM’s Fragrance Ingredient Safety Assessments and managing RIFM’s photoallergy research. In addition\, she is engaged in collaborations with industry leaders to investigate new approaches to evaluate the photoallergenic potential of fragrance materials. Before RIFM\, Gretchen worked in the Allergy and Asthma Discovery Research group at Schering Plough Research Institute. She evaluated lead development candidates for treating pulmonary disorders\, refined measurement of allergic airway disease\, and investigated markers of airway inflammation. Gretchen is a member of the Society of Toxicology (SOT) and both the European and American Societies of Photobiology (ESP & ASP\, respectively). \n\n  \nNew GARD data on skin sensitization testing: “difficult-to-test” substances and quantitative potency assessment and regulatory testing of Medical Devices \n\n​Andy Forreryd\, PhD\nScientific Liaison @ SenzaGen\nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning. He is also co-developer of the GARD platform for the assessment of chemical sensitizers and is the inventor of two patents related to the technology. \n 
URL:https://senzagen.com/event/2023-sot-recap-webinar/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Lime_RECAP-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230322T080000
DTEND;TZID=Europe/Stockholm:20230323T170000
DTSTAMP:20260429T221108
CREATED:20221109T100611Z
LAST-MODIFIED:20230322T130845Z
UID:30088-1679472000-1679590800@senzagen.com
SUMMARY:2023 SOT Annual Meeting & ToxExpo
DESCRIPTION:Meet us at this year’s SOT\nCome meet us at our booth and join our hosted session to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development. \n \n  \n  \n\nExhibitor-Hosted Session\n\n\n  \n  \n\nPosters\n\n🎫 P117 |  Joint poster with ExxonMobil Biomedical Sciences\n#3016: Mar 20\, 9:00am-10:45am: Assessing the Utility of the Genomic Allergen Rapid Detection (GARDskin) Assay to Detect Dermal Sensitization Potential in UVCBs and Formulated Lubricant Products \n🎫 P329 | Joint poster with Research Institute for Fragrance Materials (RIFM)\n#4456: Mar 22\, 10:45am-12:30pm: GARDskin Dose-Response for Photosensitization: Assessment of Reference Photoirritants and Photoallergens \n🎫 P293 | Poster on Medical Device\n#4422: Mar 22\, 10:45am-12:30pm: In Vitro Assays for Assessment of Skin Sensitization Hazard and Potency of Isobornyl Acrylate \n🎫 P151 | Joint poster with International Flavors & Fragrances Inc. (IFF) and Research Institute for Fragrance Materials (RIFM)\n#5050: Mar 23\, 8:30am-11:30am: Gardskin Dose-Response Assay for Pod Determination of Fragrance Materials and Its Application in Conducting Quantitative Risk Assessment (QRA) \n\nExpanded toxicology testing services\n\nAt our booth\, we will introduce you to how you can use in vitro methods for the biological evaluation of medical devices and how we can support you with tailored toxicology advisory services. We will also present our expanded services for in vitro regulatory toxicity testing. \nFind out about our expanded services and expertise\n 
URL:https://senzagen.com/event/2023-sot/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/Newsletter-banner-SOT.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230222T160000
DTEND;TZID=Europe/Stockholm:20230222T170000
DTSTAMP:20260429T221108
CREATED:20230131T145829Z
LAST-MODIFIED:20230131T150057Z
UID:30336-1677081600-1677085200@senzagen.com
SUMMARY:Webinar: Overcoming challenges in skin sensitization testing with GARDskin OECD TG 442E
DESCRIPTION:Free webinar on Feb 22\, 2023 | 4pm CET | 10am EST \nTogether with guest speakers Dr Marco Corvaro\, Technical Team Leader\, Regulatory Toxicology at Corteva Agriscience and Gretchen Ritacco\, Principal Scientist at the Research Institute for Fragrance Materials (RIFM)\, we will discuss the challenges in skin sensitization testing and present new scientific data on agrochemical formulations\, “difficult-to-test” substances\, potency assessment and the potential to further broaden the applicability of the GARD assay to assess the endpoint of photosensitization. \n  \n \n\nAgenda \n\nChallenges in skin sensitization assessment.\nUpdate on the recent OECD approval of GARD®skin TG 442E.\nCase studies on “difficult-to-test” substances and quantitative potency assessment.\nCase study: Investigating the applicability domain of GARD®skin and GARD®potency for agrochemical formulations. Presented by Dr Marco Corvaro\, Corteva Agrisciences.\nNew application: An introduction to photosensitization and why there is a need for development of predictive assays capable of discriminating between photosensitization and photoirritancy.\n\n  \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \nOvercoming challenges in skin sensitization testing with GARD®skin OECD TG 442E  \nThe field of skin sensitization assessment is rapidly evolving. New Approach Methodologies (NAMs) have been developed to increase predictivity\, broaden the applicability and to provide reliable quantitative and qualitative potency assessments. \nAs the first and only genomics and machine learning-based method\, GARDskin has been included into OECD Test Guideline 442E for in vitro skin sensitization. The scientific data published in the TG confirms the high performance and broad applicability of the method\, bringing new opportunities to the field of in vitro skin sensitization testing. \nPhototoxicity is a term used to describe chemicals which has the inherent potential to become photoactivated when exposed to UV-light\, giving rise to otherwise dormant adverse effects. Such effects may include both irritation and sensitization. In terms of risk management\, the distinction of the two types of chemicals is important\, as the hazardous exposure effects of photoirritants can be reduced by concentration limits\, whereas photoallergenic properties currently results in a ban of the chemical at hand. SenzaGen and the Research Institute for Fragrance Materials (RIFM) are collaborating to investigate and develop New Approach Methods (NAMs) for identification and discrimination of photosensitizers from photoirritants. Preliminary data from the incorporation of an UV-exposure step to the original protocol of GARDskin Dose-Response will be illustrated\, and the potential of this approach to simultaneously identify and distinguish between photosensitization and photoirritation will be discussed.  \n\nSpeakers \nDr Marco Covaro\nTechnical Team Leader\, Regulatory Toxicology at Corteva Agriscience\nDr Corvaro has more than 15 years of experience in the safety evaluation of regulated products in a variety of industry sectors. He is a European Registered Toxicologist (ERT) and works as technical lead in Regulatory Toxicology at Corteva. He also acts as the group focal point for activities in the 3R area\, including reduction and alternatives to animal toxicity testing and has been part of several technical expert groups at OECD\, EChA\, ECETOC\, EPAA\, CLE (previously ECPA and EuropaBio) aimed at scientific consensus building and science communication within the regulatory community. \nGretchen Ritacco\nPrincipal Scientist\, Dermatotoxicology at RIFM\nGretchen Ritacco leads the Photosafety program at the Research Institute for Fragrance Materials (RIFM). Her duties include evaluating fragrance materials in support of RIFM’s Fragrance Ingredient Safety Assessments and managing RIFM’s photoallergy research. In addition\, she is engaged in collaborations with industry leaders to investigate new approaches to evaluate the photoallergenic potential of fragrance materials. Before RIFM\, Gretchen worked in the Allergy and Asthma Discovery Research group at Schering Plough Research Institute. She evaluated lead development candidates for treating pulmonary disorders\, refined measurement of allergic airway disease\, and investigated markers of airway inflammation. Gretchen is a member of the Society of Toxicology (SOT) and both the European and American Societies of Photobiology (ESP & ASP\, respectively). \nDr Andy Forreryd\nScientific Liaison at SenzaGen\nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning. He is also co-developer of the GARD platform for the assessment of chemical sensitizers and is the inventor of two patents related to the technology. \n\nREGISTER NOW\n\n 
URL:https://senzagen.com/event/webinar-overcoming-challenges-in-skin-sensitization-testing-with-gardskin-oecd-tg-442e/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/Event-calendar_845x320.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230215
DTEND;VALUE=DATE:20230218
DTSTAMP:20260429T221108
CREATED:20230111T132555Z
LAST-MODIFIED:20230111T154919Z
UID:30279-1676419200-1676678399@senzagen.com
SUMMARY:PCHi 2023 Expo & SHSOT Forum
DESCRIPTION:Personal Care and Homecare Ingredients 2023 Expo & Shanghai Society of Toxicology Forum\n15-17 February 2023 @The China Import and Export Fair Complex\, Guangzhou\, China\nRead More
URL:https://senzagen.com/event/pchi-2023-expo-shsot-forum/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/01/msg98-1-2022-07-21-5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230209
DTEND;VALUE=DATE:20230210
DTSTAMP:20260429T221108
CREATED:20230112T112845Z
LAST-MODIFIED:20230112T114227Z
UID:30297-1675900800-1675987199@senzagen.com
SUMMARY:VitroScreen Seminar on Substance Based Medical Devices
DESCRIPTION:VitroScreen has been a pioneer in developing and proposing pre-clinical experimental protocols on 3D reconstructed human tissue models: they are currently applied to demonstrate the mechanism of action of SBMD and they are relevant to comply with the safety and efficacy requirements of the EU MDR 2017/745. \nThe seminar has the ambition to open a discussion on MDCG 2022-5 with stakeholders involved in Medical Devices (Health Authorities\, Notified Bodies\, Academia\, Industry and ISO representative) analyzing the state of the art of scientific approaches to qualification and classification issues. \nTo view the program and instruction for registration\, please\, click here.
URL:https://senzagen.com/event/vitroscreen-seminar-on-substance-based-medical-devices/
LOCATION:Excelsior Hotel Gallia\, Milan\, Italy
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230124T160000
DTEND;TZID=Europe/Stockholm:20230124T170000
DTSTAMP:20260429T221108
CREATED:20221118T150607Z
LAST-MODIFIED:20230120T152436Z
UID:30122-1674576000-1674579600@senzagen.com
SUMMARY:Webinar: Safety and Efficacy Evaluation of Cosmetic Products and Ingredients
DESCRIPTION:How to integrate innovative in vitro test methods\nIn this joint webinar\, we will present an overview of innovative in vitro methods and how to integrate them into the evaluation of safety and efficacy of cosmetic products and ingredients. The webinar will start with a recorded presentation followed by a live Q&A session. If you cannot attend the live event\, register now to get access to the recording. \n  \n \nKey topics and speakers\n \n\nRegister now
URL:https://senzagen.com/event/webinar-safety-and-efficacy-evaluation-of-cosmetic-products-and-ingredients/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/French-cosmetics-webinar-banner_website-v1-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260429T221108
CREATED:20221021T092257Z
LAST-MODIFIED:20221128T115912Z
UID:29974-1669852800-1670025599@senzagen.com
SUMMARY:2022 Aromadays
DESCRIPTION:Dec 1-2 | Avignon\, Palais des Papes\, France\nMeet us at the 2022 Aromadays conference in Avignon and talk to our specialists regarding the application of the GARD assays for essential oils. \nScientific session\n09:45 CET\, Dec 2\, 2022\nAre there limitations to the applicability of toxicological tests to essential oils ? Focus on the GARD®skin test\nExiste-t-il des limites à l’application des tests toxicologiques aux Huiles Essentielles? Focus sur le test GARD®skin\nCristina ONCINS PALLAS\, Chargée de l’évaluation toxicologique des ingrédients – CONSORTIUM HE\nDr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen\nRead more here
URL:https://senzagen.com/event/2022-aromadays/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/10/logo_aromadays.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221124T080000
DTEND;TZID=Europe/Stockholm:20221125T170000
DTSTAMP:20260429T221108
CREATED:20221102T083023Z
LAST-MODIFIED:20221121T123857Z
UID:30037-1669276800-1669395600@senzagen.com
SUMMARY:2022 SFT
DESCRIPTION:Nov 24-25 | Avignon\, France\nMeet us at the 2022 annual meeting of the French Society of Toxicology in Avignon and talk to our skin sensitization experts regarding the new opportunities the GARD assays have brought to the field. \nWe will also present a poster: “Quantitative sensitizing potency assessment using GARD®skin Dose-Response”. \nPresented by: Dr Andy Forreryd & Anna Chérouvrier Hansson\, Scientific Liaison & Business Development – SenzaGen
URL:https://senzagen.com/event/2022-sft/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/11/logo_sft.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221121
DTEND;VALUE=DATE:20221126
DTSTAMP:20260429T221108
CREATED:20220825T140904Z
LAST-MODIFIED:20221114T140547Z
UID:29773-1668988800-1669420799@senzagen.com
SUMMARY:2022 ESTIV
DESCRIPTION:Booth#5 | Nov 21-25 | Sitges (Barcelona)\, Spain\nAre you attending the 2022 ESTIV International Congress? Come meet us at our booth and join our scientific sessions to hear the latest news about GARD and how the assays are used for skin sensitization testing. We will also introduce you to our expanded services for in vitro regulatory toxicity testing and how you can use in vitro methods for the biological evaluation of medical devices. \n\nScientific presentations\n\n“In vitro assessment of skin sensitizing potential of process-related impurities in polymeric materials during product development”\nSpeaker:  Dr Andy Forreryd @SenzaGen \nTuesday\, November 22nd\, 2022\, 11:00-13:00 | Session 3a. Models\, biomarkers and assays for systemic and immune toxicity \n“Biocompatibility of medical devices: eye irritation of preserved and unpreserved eye drops on HCE model”\nSpeaker:  Dr Laura Ceriotti @VitroScreen \nThursday\, November 24th\, 2022\, 11:00-12:40| Session 8a – In vitro methods for safety assessment of medical devices \n\n\nPosters\n\n\nJoint poster with Sonova: #307 – “In vitro method for quantitative potency assessment of skin sensitizers during development of novel materials for intended use in medical devices”\nPoster presentation by Dr Rose-Marie Jenvert @SenzaGen \nSession 8a. In vitro methods for safety assessment of medical devices \nJoint poster with Coty: #275 – “Effect of a modulator on the skin sensitization potency of cosmetic fragrance formulations”\nPoster presentation by Dr Carine Linossier @Coty \nSession 4b. Local toxicity testing (safety and efficacy) \n  \n 
URL:https://senzagen.com/event/2022-estiv/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/ESTIV_Screenshot-2022-08-25.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221026T160000
DTEND;TZID=Europe/Stockholm:20221026T170000
DTSTAMP:20260429T221108
CREATED:20220830T120449Z
LAST-MODIFIED:20221017T122725Z
UID:29801-1666800000-1666803600@senzagen.com
SUMMARY:Webinar: How to use in vitro assays in your biological evaluation
DESCRIPTION:In this webinar\, our Medical Device and ISO expert Dr Rose-Marie Jenvert will tell you more about how you can use in vitro methods for the biological evaluation of medical devices\, now offered at our GLP-certified laboratories. She will also introduce you to our expanded medical device offering and how we can help you to comply with MDR. \nThe webinar will last around 45 minutes\, followed by a live Q&A. Even If you cannot attend the live event\, make sure to register to get access to the recording. \n  \n  \n\nKey takeaways\n\nAttendees will gain insights into: \n💡 In vitro biocompatibility testing now in ISO 10993 \n💡 GARD® compatible with both saline and oil \n💡 GARD® for quantitative potency assessment during product development \n💡 3Rs strategy in compliance with MDR Rule 21  \n\nSpeaker\n\n \n\nHighly accurate and ethical alternatives \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nOur GLP-certified laboratories offer an in vitro biocompatibility package that includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, providing a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human-relevant results with higher accuracy and fewer false-positive results compared to the rabbit model. \nSkin sensitization with GARD®  \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and  10993-10:2021\, thus mimicking the intended use of the device when in contact with skin.  \n\nRegister now
URL:https://senzagen.com/event/webinar-how-to-use-in-vitro-assays-in-your-biological-evaluation/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/08/Webinar-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221019
DTEND;VALUE=DATE:20221022
DTSTAMP:20260429T221108
CREATED:20220825T135715Z
LAST-MODIFIED:20220825T135806Z
UID:29760-1666137600-1666396799@senzagen.com
SUMMARY:2022 ASCCT
DESCRIPTION:Oct 19-21 | Chapel Hill\, N.C.\,USA\nMore information coming soon!
URL:https://senzagen.com/event/2022-ascct/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/22179-RAD-ASCCT-11th-Annual-Meeting-Graphics-Banner-CROPPED-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20221012T160000
DTEND;TZID=Europe/Stockholm:20221012T170000
DTSTAMP:20260429T221108
CREATED:20220920T133458Z
LAST-MODIFIED:20220923T095041Z
UID:29883-1665590400-1665594000@senzagen.com
SUMMARY:Webinar: Recap on SenzaGen’s 2022 ICT Scientific Session
DESCRIPTION:New GARD® data on agrochemicals\,”difficult-to-test” substances and potency assessments\n\n – In vitro skin sensitization testing: New opportunities for hazard and quantitative potency assessment using genomics and machine learning technology\nIn case you missed SenzaGen’s scientific session at this year’s ICT\, we are pleased to offer you a new opportunity! We will present new scientific data on agrochemical formulations generated in collaboration with Corteva Agriscience\, “difficult-to-test” substances and potency assessment. \nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording. \n  \n \n  \n \n  \n\nRegister now
URL:https://senzagen.com/event/webinar-recap-on-senzagens-2022-ict-industry-symposium/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/09/Recap-webinar-banner-for-website_v4-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221007
DTSTAMP:20260429T221108
CREATED:20220707T081238Z
LAST-MODIFIED:20220926T135947Z
UID:29631-1664928000-1665100799@senzagen.com
SUMMARY:2022 Biocompatibility Matters
DESCRIPTION:Oct 5-6 | Copenhagen\, Denmark\nMeet SenzaGen at 2022 Biocompatibility Matters\, a two-day conference in Copenhagen. SenzaGen’s Medical Device specialist and ISO expert Dr Rose-Marie Jenvert will speak on the topic “New approaches to in vitro sensitization – regulatory acceptance”. \n\nKey takeaways:\n\n* An introduction to in vitro assays for skin sensitization\, ISO 10993-10\n* The potential to use polar and non-polar extracts in in vitro assays\n* How in vitro assays can gain regulatory acceptance\n* Case studies on in vitro skin sensitization assessment of medical devices \n\nRead more and register\n\n 
URL:https://senzagen.com/event/2022-biocompatibility-matters/
LOCATION:Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/07/BM-logo@2x-e1622186428171.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220922
DTSTAMP:20260429T221108
CREATED:20220427T123124Z
LAST-MODIFIED:20220916T085253Z
UID:29390-1663718400-1663804799@senzagen.com
SUMMARY:2022 ICT/IUTOX/EUROTOX
DESCRIPTION:2022 International Congress of Toxicology – “Uniting in Toxicology”\n\nDiscussions at this year’s ICT\nNew opportunities for skin sensitization testing with GARDskin OECD TG 442E\n\nCome visit us at our booth and join our industry symposium to learn how the high performance and broad applicability of the GARDskin method bring new opportunities to the field of in vitro skin sensitization testing. We will provide user cases to show how GARD can be used to fill data gaps during regulatory testing and R&D. \n\nIndustry symposium\nNew GARD data on “difficult-to-test” substances and potency assessment\n\nSep 20\, 12:00-13:00 CEST @Room 0.09 Athens\n \nREGISTER HERE TO SECURE YOUR SEAT\n(click the link or fill out the form below)\nFill out my online form.\n \n\nHighlights at our booth #34\nDiscover our expanded in vitro toxicity testing services\n\nDo you have “difficult-to-test” samples or are you looking for quantitative skin sensitizing potency information? Come discuss your testing needs with us and learn more about GARD and our expanded in vitro toxicity testing services for cosmetics\, chemicals and medical devices. \nFIND OUT ABOUT OUR SERVICES AND EXPERTISE
URL:https://senzagen.com/event/2022-ict-iutox-eurotox/
LOCATION:Maastricht
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2022/04/LIME-banner-v7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220914T143000
DTEND;TZID=Europe/Stockholm:20220914T180000
DTSTAMP:20260429T221108
CREATED:20220825T134032Z
LAST-MODIFIED:20220826T062417Z
UID:29741-1663165800-1663178400@senzagen.com
SUMMARY:2022 MVA MedTech Network meeting
DESCRIPTION:Drug device combination products and substance-based medical devices\nSep 14 | Copenhagen\, Denmark\nMedicon Valley Alliance\, together with member company Innokas Medical\, have the pleasure to invite you to the Medicon Valley Alliance MedTech Network meeting\, on the 14th of September\, focusing on drug-device combination products and substance-based medical devices. \n\nSign up here\n\nThe market for drug-device combination products is growing and it is anticipated that up to one in three medical products in development is a combination of a drug/substance and a MedTech product. Drivers for the growth in combination products is the rise of patients suffering from chronic diseases such as diabetes\, cancer\, and respiratory problems as well as growth in the home-based health care market and technological advancements. \nWhen searching for the correct regulatory approval in the EU the primary mode of action (PMOA) will define the regulatory path for your products. For example\, if the action of your medicinal substance is ancillary\, then your product is regulated as a medical device under MDR\, on the other hand\, if the product is mainly of the medicinal substance the product will be regulated as a medicinal product.  A substance with a therapeutic effect can be either a medicinal product/drug or a medical device\, depending on its primary mechanism of action. \nDeveloping this type of products is associated with a high level of complexity. For combination products\, you need to navigate two of the most intensely regulated pathways in one go: for pharmaceuticals and medical devices. The re-classification of substance-based medical devices according to MDR means a more extensive risk assessment involving scientific evidence of PMOA. \nIn this MVA MedTech Network meeting\, we would like to invite you to hear from experts in the area of developing drug-device combination products and substance-based medical devices as well as hearing from companies sharing their experiences\, challenges and solutions.\nIf you are interested in sharing your company’s approach and experiences with drug-device combination products and/or substance-based medical devices and to speak at the meeting on the 14th of September\, please reach out to Sofia Norås\, sn@mva.org. \nAgenda\n14.30 – 15.00  Registration\, networking and light refreshments\n15.00 – 15.10  Welcome\, Anette Steenberg\, CEO\, Medicon Valley Alliance; Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.10 – 15.15  IP and patents in combination products\, Pernille Winding Gojkovic\, CEO\, Høiberg European Patent Attorneys\n15.15 – 15.45  Challenging development with combination products\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n15.45 – 16.05  Substance-based medical devices\, Rose-Marie Jenvert\, Product Manager GARD applications SenzaGen\n16.05 – 16.40  Company cases TBC\n16.40 – 17.00  Concluding remarks: Building collaborations between organisations & Q&A to all speakers\, Satu Päiväläinen\, Specialist\, Clinical affairs and IVD\, Innokas Medical\n17.00 – 18.00  Networking
URL:https://senzagen.com/event/2022-mva-medtech-network-meeting/
LOCATION:Medicon Valley Alliance\, Auditorium\, Arne Jacobsens Alle 15 \, 2300 Ørestad City\, Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2022/08/220914-medtech-network-banner-1080.jpg
END:VEVENT
END:VCALENDAR